Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem

Approximately 20% of invasive breast cancers have upregulation/gene amplification of the oncogene human epidermal growth factor receptor-2 (HER2/ErbB2). Of these, some also express steroid receptors (the so-called Luminal B subtype), whereas others do not (the HER2 subtype). HER2 abnormal breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahdan-Alaswad, Reema, Liu, Bolin, Thor, Ann D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090587/
https://www.ncbi.nlm.nih.gov/pubmed/35582612
http://dx.doi.org/10.20517/cdr.2019.92

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090587/
https://www.ncbi.nlm.nih.gov/pubmed/35582612
http://dx.doi.org/10.20517/cdr.2019.92

Ejemplares similares